Stay updated on Nivolumab and Urelumab in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Urelumab in Bladder Cancer Clinical Trial page.
Latest updates to the Nivolumab and Urelumab in Bladder Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no study details, eligibility criteria, or outcomes appear to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe study locations were updated to include California, Colorado, Illinois, Maryland, and New York; the page revision was updated to v3.3.3; and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.7%
- Check59 days agoChange DetectedRevision: v3.3.2 added, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check66 days agoChange DetectedRemoved the government funding status notice from the page, which previously warned that information might not be up to date and that NIH operations could be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check81 days agoChange DetectedNo additions or deletions were detected on the page; the content appears unchanged.SummaryDifference0.5%
- Check109 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference3%
Stay in the know with updates to Nivolumab and Urelumab in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Urelumab in Bladder Cancer Clinical Trial page.